Obi Pharma Inc.

Nan-Hsuan Wang

Yu-Hsin Lin

Yu-Chen Lin

I-Ju Chen

Cheng-Der Tony Yu

Cheng-Chi Wang

Yih-Huang Hsieh

Wei Lee

Yi-Chien Tsai

Teng-Yi Huang

Wei-Han Lee

Cheng Der Yu

Yin-Cheng Hsieh

Pu-Ling Hu

Chung-Hao Chang

Yih Huang Hsieh

Chung Hao Chang

Cheng Der Tony Yu

Wei Han Lee

I Ju Chen

The present invention provides vaccines comprising carbohydrate antigen conjugated to a diphtheria toxin (DT) as a carrier protein, wherein the ratio of the number of carbohydrate antigen molecule to the carrier protein molecule is higher than 5:1. Also disclosed herein is a novel saponin adjuvant and methods to inhibit cancer cells, by administering an effective amount of the vaccine disclose herein.

Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

The present disclosure relates to novel glycosynthase enzymes for glycoprotein engineering and/or homogeneous antibody remodeling. The enzyme variants, termed EndoSd-D232M and EndoSz-D234M, contain the glycan conjugation and/or modification activity at the conserved N297 glycosylation site of Fc region of an exemplary antibody. It has been demonstrated that the glycosynthase activities of EndoSd-D232M and EndoSz-D234M can be applied to various mAbs targeting different receptors, including, but not limited to, Globo H, SSEA-4, SSEA-3 series of receptors (OBI-888; Globo H ganglioside), Herceptin (Her 2 receptor), Perj eta (Her 2 receptor) and Vectibix (EGFR receptor). It has been found that both mAb-GlcNAc and mAb-GlucNAc(F) were suitable substrates for both EndoSd-D232M and EndoSz-D234M. The ADCC assay of related products, OBI-888-G2S2 and Herceptin-G2S2, showed that the remodeled homogeneous antibody, mAb-G2S2, has an increased relative activity ranging from 3 to 26 folds.

Glycosynthase variants for glycoprotein engineering and methods of use

Growing community of inventors

Taipei, Taiwan

Nan-Hsuan Wang